Radiographic assessment of photodynamic therapy as an adjunctive treatment on induced periodontitis in immunosuppressed rats.
OBJECTIVE
The aim of this study was to assess radiographically the effect of photodynamic therapy (PDT) as an adjunctive treatment to scaling and root planing (SRP) on induced periodontitis in dexamethasone-induced immunosuppressed rats.


METHODS
The animals were divided into 2 groups: ND group (n=60): saline treatment; D group (n=60): dexamethasone treatment. In both ND and D groups, periodontal disease was induced by the placement of a ligature in the left first mandibular molar. After 7 days, ligature was removed and all animals received SRP, being divided according to the following treatments: SRP: saline and PDT: phenothiazinium dye (TBO) plus laser irradiation. Ten animals per treatment were killed at 7, 15 and 30 days. The distance between the cementoenamel junction and the height of the alveolar bone crest in the mesial surface of the mandibular left first molars was determined in millimeters in each radiograph. he radiographic values were analyzed statistically by ANOVA and Tukey's test at a p value <0.05.


RESULTS
Intragroup radiographic assessment (ND and D groups) showed that there was statistically significant less bone loss in the animals treated with PDT in all experimental periods compared to those submitted to SRP. Intergroup radiographic analysis (ND and D groups) demonstrated that there was greater bone loss in the ND group treated with SRP compared to the D group treated with PDT at 7 and 30 days.


CONCLUSIONS
PDT was an effective adjunctive treatment to SRP on induced periodontitis in dexamethasone-induced immunosuppressed rats.
Fernandes
Leandro Araújo
LA
Department of Surgery and Integrated Clinic, Araçatuba Dental School, São Paulo State University, Araçatuba, SP, Brazil. leandroataunesp@ig.com.br
Martins
Thiago Marchi
TM
de Almeida
Juliano Milanezi
JM
Theodoro
Letícia Helena
LH
Garcia
Valdir Gouveia
VG
D016301:Alveolar Bone Loss / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000628:therapy; D000539:Alveolar Process / Q000000981:diagnostic imaging; D000818:Animals; D003131:Combined Modality Therapy; D012534:Dental Scaling; D003907:Dexamethasone / Q000009:adverse effects; D017823:Furcation Defects / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000628:therapy; D005938:Glucocorticoids / Q000009:adverse effects; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects; D054023:Lasers, Semiconductor / Q000627:therapeutic use; D028022:Low-Level Light Therapy; D008297:Male; D008334:Mandible / Q000000981:diagnostic imaging; D008963:Molar / Q000000981:diagnostic imaging; D010518:Periodontitis / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000628:therapy; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011859:Radiography; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D016745:Root Planing; D013997:Time Factors; D014048:Tolonium Chloride / Q000627:therapeutic use; D019237:Tooth Cervix / Q000000981:diagnostic imaging
D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D017319:Photosensitizing Agents; D014048:Tolonium Chloride; D003907:Dexamethasone